Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin α)

Reproductive BioMedicine Online

Volumn 13, Issue 2, 2006, Pages 179-193

  Lispi, M ^a   Bassett, Robert ^a   Crisci, C ^a   Mancinelli, M ^a   Martelli, F ^a   Ceccarelli, D ^a   De Bellis, C ^a   Mendola, D ^a  

^a Serono International SA   (Switzerland)

Author keywords

Contaminants; Follitropin ; FSH; Quality control; Urofollitropin

Indexed keywords

RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG POTENCY; DRUG PURIFICATION; DRUG PURITY; DRUG QUALITY; FEMALE; NONHUMAN; OVULATION INDUCTION; RAT;

EID: 33747045540     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60613-X     Document Type: Article

References (44)

1. Amoresano A, Siciliano R, Orru S et al. 1996 Structural characterisation of human recombinant glycohormones follitropin, lutropin and choriogonadotropin expressed in Chinese hamster ovary cells. European Journal of Biochemistry 242, 608-618.
2. Bagatti G, Crisci C, Datalo A et al. 2001 Characterization and comparison of recombinant human follicle-stimulating hormones. Journal of Clinical Research 4, 91-104.
3. Balen A, Lumholz IB 2005 Consensus statement on the biosafety of urinary-derived gonadotrophins with respect to Creutzfeldt-Jakob disease. Human Reproduction 20, 2994-2999.
4. Bassett R, Driebergen R 2005a Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reproductive BioMedicine Online 10, 169-177.
5. Bassett R, Ceccarelli D, Crisci C et al. 2005b Comparative analytical characterisation of two commercial human follicle stimulating hormones extracted from human urine. Current Medical Research 21, 899-905.
6. Bergh C, Howles C, Borg K et al. 1997 Recombinant human follicle stimulating hormone (r-hFSH; Gonal-f) versus highly purified urinary FSH (Metrodin HP): results of a randomised comparative study in women undergoing assisted reproductive techniques. Human Reproduction 12, 2133-2139.
7. D'Antonio M, Borrelli F, Datola A et al. 1999 Biological characterization of recombinant human follicle stimulating hormone isoforms. Human Reproduction 14, 1160-1167.
8. Driebergen R, Baer G 2003 Quantification of follicle stimulating hormone (follitropin alfa): is in vivo bioassay still relevant in the recombinant age? Current Medical Research and Opinion 19, 41-46.
9. European Patent for IBSA, No. EP 0882064B1 reports a purification step...'....by affinity chromatography column having an antraquinone derivate as ligand, selectively eluting contaminant proteins and FSH or LH with alkaline pH solution.'
10. Furukawa H, Doh-ura K, Okuwaki R et al. 2004 A pitfall in diagnosis of human prion diseases using detection of protease-resistant prion protein in urine: contamination with bacterial outer membrane proteins. Journal of Biological Chemistry 279, 23661-23667.
11. Gervais A, Hammel Y-A, Baer G et al. 2003 Glycosylation of human recombinant gonadotrophins: characterisation and batch-to-batch consistency. Glycobiology 13, 179-189.
12. Giudice E, Crisci C, Altarocca M et al. 2001 Characterisation of a partially purified human menopausal gonadotrophin preparation. Journal of Clinical Research 4, 27-34.
13. Giudice E, Crisci C, Eshkol A, Papoian R 1994 Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterisation of non-gonadotrophin proteins. Human Reproduction 9, 2291-2299.
14. Harris S, Anobile C, McLoughlin J et al. 1996 Internal carbohydrate complexity of the oligosaccharide chains of recombinant human follicle stimulating hormone (Puregon, Org 32489): a comparison with Metrodin and Metrodin-HP. Molecular Human Reproduction 2, 807-811.
15. Horsman G, Talbot J, McLoughlin J et al. 2000 A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon. Human Reproduction 15, 1898-1902.
16. Howles C 1996 Genetic engineering of human FSH (Gonal-f). Human Reproduction Update 2, 172-191.
17. Hugues J-N, Barlow DH, Rosenwaks Z et al. 2003 Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparation. Reproductive BioMedicine Online 6, 185-190.
18. Kauffman H, Hovenga H, de Bruijn H, Beintema J 1999 Eosinophil-derived neurotoxin (EDN) levels in commercial human urinary preparations of glycoprotein hormones. European Journal of Obstetrics, Gynecology and Reproductive Biology 82, 111-113.
19. Keck C, Bassett R, Ludwig M 2005 Factors influencing response to ovarian stimulation. Reproductive BioMedicine Online 11, 562-569.
20. Kragh-Hansen U, Chuang V, Otagiri M 2002 Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biological and Pharmaceutical Bulletin 25, 695-704.
21. Lambert A, Talbot J, Anobile C et al. 1998 Gonadotropin heterogeneity and biopotency: implications for assisted reproduction. Molecular Human Reproduction 4, 619-629.
22. Lambert A, Rodgers M, Mitchell R et al. 1995 In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), metrodin and metrodin-HP. Human Reproduction 10, 1928-1935.
23. Ludwig M, Felberbaum R, Diedrich K, Lunenfeld B 2002 Ovarian stimulation: from basic science to clinical application. Reproductive BioMedicine Online 5 (Suppl. 1), 73-86.
24. Lunenfeld B 2001 Development of gonadotrophins for clinical use. Reproductive BioMedicine Online 4 (Suppl. 1), 11-17.
25. Mulders JW, Derksen M, Swolfs A et al. 1997 Prediction of the in-vivo biological activity of human recombinant follicle stimulating hormone using quantitative isoelectric focusing. Biologicals 25, 269-281.
26. Olijve W, De Boer W, Molders J et al. 1996 Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Molecular Human Reproduction 2, 371-382.
27. Out H, Driessen S, Mannaerts B et al. 1997 Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertility and Sterility 68, 138-142.
28. Padmanabhan V, Lang L, Sonstein J et al. 1988 Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis. Journal of Clinical Endocrinology and Metabolism 67, 465-473.
29. Reichl H, Balen A, Jansen M 2002 Prion transmission in blood and urine: what are the implications for recombinant and urinary-derived gonadotropins? Human Reproduction 17, 2501-2508.
30. Rose MP, Gaines Das RE, Balen AH 2000 Definition and measurement of follicle stimulating hormone. Endocrine Review 21, 5-22.
31. Seeger H, Heikenwalder M, Zeller N et al. 2005 Coincident scrapie infection and nephritis lead to prion excretion. Science 310, 324-326.
32. Serban A, Legname G, Hansen K et al. 2004 Immunoglobulins in urine of hamsters with scrapie. Journal of Biological Chemistry 279, 48817-48820.
33. Shaked G, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R, 2001. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. Journal of Biological Chemistry 276, 31479-31482.
34. Siebold B 1996 Physiochemical characterization of recombinant human follicle stimulating hormone. Human Reproduction 11 (Suppl. 1), 109-115.
35. Steelman S, Pohley F 1953 Assay of the follicle-stimulating hormone based on the augmentation with human chorionic gonadotrophin. Endocrinology 53, 604-616.
36. Ulloa-Aguirre A, Craviato A, Damian-Matsumura P et al. 1992 Biological characterisation of the naturally occurring analogues of intrapituitary human follicle stimulating hormone. Human Reproduction 7, 23-30.
37. Van de Weijer B, Mulders J, Bos E et al. 2003 Compositional analyses of a human menopausal preparation extracted from urine (menotropin). Identification of some of its major impurities. Reproductive BioMedicine Online 7, 547-557.
38. Wolfenson C, Groisman J, Couto A et al. 2005 Batch to batch consistency of human-derived gonadotropin preparations compared with recombinant preparations. Reproductive BioMedicine Online 10, 442-454.
39. Yang D, Chen Q, Rosenberg H et al. 2004 Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. Journal of Immunology 173, 6134-6142.
40. Yang D, Rosenberg H, Chen Q et al. 2003 Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 9, 3396-3403.
41. Yarram S, Jenkins J, Cole L et al. 2004 Epidermal growth factor contamination and concentrations of intact human chorionic gonadotropin in commercial preparations. Fertility and Sterility 82, 232-233.
42. Yding Andersen C, Westergaard L, van Wely M 2004 FSH isoforms composition of commercial gonadotropin preparations: a neglected aspect? Reproductive BioMedicine Online 9, 231-236.
43. Yeko T, Pasqualini SR, Alam V, Tredway D 2004 Cumulative ovulation and pregnancy rates according to recombinant human follicle stimulating hormone (r-hFSH) dosing: comparison of a new formulation of follitropin alfa in vials versus the standard formulation of follitropin alfa in ampules. Fertility and Sterility 82 (Suppl. 2), s119
44. Zambrano E, de Tomaasi B, Cardenas M, Ulloa-Aguirre A 1996 Studies on the relative in-vitro biological potency of the naturally occurring isoforms of intrapituitary follicle stimulating hormone. Mol Human Reproduction 2, 563-571.